Association between APOC1 polymorphism and Alzheimer's disease: a case-control study and meta-analysis

PLoS One. 2014 Jan 31;9(1):e87017. doi: 10.1371/journal.pone.0087017. eCollection 2014.

Abstract

Background: Previous association studies examining the relationship between the APOC1 polymorphism and susceptibility to Alzheimer's disease (AD) have shown conflicting results, and it is not clear if an APOC1 variant acts as a genetic risk factor in AD etiology across multiple populations.

Methods: To confirm the risk association between APOC1 and AD, we designed a case-control study and also performed a meta-analysis of previously published studies.

Results: Seventy-nine patients with AD and one hundred fifty-six unrelated controls were included in case-control study. No association was found between the variation of APOC1 and AD in stage 1 of our study. However, our meta-analysis pooled a total of 2092 AD patients and 2685 controls. The APOC1 rs11568822 polymorphism was associated with increased AD risk in Caucasians, Asians and Caribbean Hispanics, but not in African Americans. APOE ε4 carriers harboring the APOC1 insertion allele, were more prevalent in AD patients than controls (χ(2) = 119.46, OR = 2.79, 95% CI = 2.31-3.36, P<0.01).

Conclusions: The APOC1 insertion allele, in combination with APOE ε4, likely serves as a potential risk factor for developing AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / ethnology
  • Alzheimer Disease / genetics*
  • Apolipoprotein C-I / genetics*
  • Apolipoprotein E4 / genetics
  • Asian People / genetics
  • Black or African American / genetics
  • Case-Control Studies
  • Gene Frequency
  • Genetic Predisposition to Disease / ethnology
  • Genetic Predisposition to Disease / genetics*
  • Genotype
  • Hispanic or Latino / genetics
  • Humans
  • Linear Models
  • Meta-Analysis as Topic
  • Polymorphism, Single Nucleotide*
  • Risk Factors
  • White People / genetics

Substances

  • APOC1 protein, human
  • Apolipoprotein C-I
  • Apolipoprotein E4

Grants and funding

This study was funded by the Natural Science Foundation of China (81061120527, 81241082, 81370445), the major funding from Beijing Hospital (BJ-2010-30), funding from the key project of clinical disciplines at the subordinate hospital, Ministry Of Health (10120101), National Department Public Benefit Research Foundation by Ministry of Health P. R. China (201302008), 12th 5 year national program from Ministry of Scientific Technology (2012BAI10B01), and the science and technology development foundation of Guangxi Zhuang Autonomous Region (1355005-6-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.